MAGE-A4 antigenic peptides and uses thereof
The invention provides antigenic peptides derived from MAGE polypeptides and presented by HLA-B37 molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.
1. An isolated peptide consisting of a fragment of SEQ ID NO:2 that comprises the amino acid sequence of SEQ ID No:5; wherein the peptide activates a CD8+ T-cell specific for MAGE-A4 when presented by an HLA Class-I molecule; wherein the isolated peptide consists of up to 10 amino acids of SEQ ID NO:2 consecutive to the N-terminus and/or the C-terminus of SEQ ID NO:5.
2. The isolated peptide of claim 1 , wherein the isolated-peptide consists of an amino acid sequence set forth as SEQ ID NO:4, or SEQ ID NO:5.
3. A composition comprising the isolated peptide of claim 1 and an isolated HLA class I- or class II-binding peptide of a non-MAGE-A4 tumor antigen.
4. A composition comprising the isolated peptide of claim 2 and an isolated HLA class I- or class II-binding peptide of a non-MAGE-A4 tumor antigen.
5. A composition comprising the isolated peptide of claim 1 and a carrier.
6. The composition of claim 5 , further comprising en adjuvant.
7. An isolated peptide consisting of a fragment of SEQ ID NO:2 that comprises the amino acid sequence set forth as SEQ ID NO:6, wherein the isolated peptide includes up to 10 amino acids of SEQ ID NO:2 consecutive to the N-terminus of SEQ ID NO:6.
8. A composition comprising the isolated peptide of claim 7 and an isolated HLA class I- or class II-binding peptide of a non-MAQE-A4 tumor antigen.
9. A composition comprising the isolated peptide of claim 7 and a carrier.
10. The composition of claim 9 , further comprising an adjuvant.
11. The isolated peptide of claim 7 , wherein the isolated-peptide consists of an amino acid sequences set forth as SEQ ID NO:3 or SEQ ID NO:6.